AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01945957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: For Phase I, subjects will be randomized to receive either 24IU (6 sprays) of active oxytocin or 6 sprays of placebo (3 sprays per nostril)~For Phase II, subjects will be randomized to receive either 8 IU or 40 IU of oxytocin.
Study NCT02902419 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wound dressing removal.
Study NCT00672412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GPO-Vir Z30 tablet
Description: Tablet consisting of ZDV 30 mg/3TC 15 mg/NVP 28 mg taken orally twice daily
Study NCT00672412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine
Description: Oral suspension containing 10 mg 3TC in each mL. Dosage depends on weight.
Study NCT00672412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevirapine
Description: Oral solution containing 10 mg NVP in each mL. Dosage depends on weight.
Study NCT00672412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zidovudine
Description: Oral solution containing 10 mg ZDV in each mL. Dosage depends on weight.
Study NCT02075229 — intervention group
Intervention type: DEVICE
Intervention: Cochlear implant
Description: A cochlear implant consists of an implantable device that electrically stimulates surviving nerve fibers within the inner ear to produce perceptions of sound in patients with significant sensorineural hearing loss.. The implanted device is controlled by an external sound processor that converts acoustic sound signals into patterns of electrical stimulation that result in sound perception for the user.
Study NCT03942627 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Program
Description: The intervention consists of two brief videos (one introducing the NICU portion of the program and one introducing the portion of the program addressing the transition home), as well as a series of mindfulness practices delivered via audio recordings to assist mothers in managing stress during the NICU stay and another series for the transition home.
Study NCT03942627 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Infant Health Education Program
Description: The active control condition consists of two brief videos (one introducing the NICU portion of the program and one introducing the portion of the program addressing the transition home), as well as a series of audio recordings providing information on infant health and development for mothers to use during the NICU stay and another series for the transition home.
Study NCT02555189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Given PO
Study NCT02555189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: Given PO
Study NCT02555189 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02555189 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT02555189 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT02555189 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy
Study NCT02555189 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO
Study NCT02555189 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA
Study NCT02555189 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo bone scan
Study NCT02555189 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT02555189 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT03398681 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferric carboymaltose
Description: Ferric Carboxymaltose solution \[Ferinject® (FCM), Vifor Pharma (Glattbrugg, Switzerland)\]
Study NCT03398681 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Normal saline)
Description: Normal saline (0.9% weight/volume (w/v) NaCl)
Study NCT03398681 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac magnetic resonance
Description: Cardiac magnetic resonance including T2\* and T1-mapping sequences
Study NCT03398681 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Cardiac magnetic resonance
Description: Cardiac magnetic resonance including T2\* and T1-mapping sequences
Study NCT02000973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: General anesthesia combined with thoracic epidural 1% lidocaine
Study NCT03438955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omacor
Description: Omacor soft capsule 4000mg for 16days
Study NCT03438955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pritor
Description: Pritor tablet 40mg for 7days
Study NCT02000973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: General anesthesia combined with thoracic epidural 0.25% bupivacaine
Study NCT02000973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: General anesthesia combined with thoracic epidural 0.3% ropivacaine
Study NCT03438955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omacor + Pritor
Description: Omacor soft capsule 4000mg + Pritor tablet 40mg for 7days
Study NCT03438955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pritor + Omacor
Description: Pritor tablet 40mg + Omacor soft capsule 4000mg for 16dyas
Study NCT01064102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetirizine Hydrochloride
Description: Cetirizine Hydrochloride Tablets 10 mg
Study NCT01064102 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetirizine Hydrochloride
Description: Cetirizine Hydrochloride Tablets 10 mg
Study NCT02314065 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT, exposure and response prevention (Face-to-face)
Description: This intervention entails different exercises aimed at exposure to health anxiety stimuli.~Treatment is delivered in a conventional manner. Participants are physically meeting with a therapist once a week.
Study NCT02314065 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT, exposure and response prevention (Internet-based)
Description: This intervention entails different exercises aimed at exposure to health anxiety stimuli.~Treatment is delivered via the Internet. Participants are guided by a therapist using an email-like communication system.
Study NCT02569372 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GC1102
Description: GC1102(Recombinant Hepatitis B Human Immunoglobulin)
Study NCT02000973 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: General anesthesia combined with thoracic epidural 0.9% normal saline
Study NCT03365739 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator 1
Description: Mango (pulp/flesh) (500 g)
Study NCT03365739 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator 2
Description: Mango (500 g) + Vitamin C (100 mg)
Study NCT03365739 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control Comparator
Description: Vitamin C (100 mg)
Study NCT03140644 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patients with thoracic sarcoidosis
Description: Ultra-low dose CT scan and MRI with UTE
Study NCT02396433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be given on day 1 of each cycle.
Study NCT02396433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Description: Eribulin will be given on days 1 and 8 of each cycle.
Study NCT02396433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7449
Description: E7449 will be given daily (days 1-21) during each cycle. Patients will continue to receive treatment until progression of disease or discontinuation due to unacceptable side effects.
Study NCT03848650 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OpSens Medical OptoWire
Description: The OptoWire is FDA approved to measure pressure in coronary vessels during diagnostic angiography and coronary interventions.~The OptoWire Deux pressure wire (OpSens Medical, Quebec, Canada) is a novel technology utilizing optical coherence technology to enhance FFR assessment of the coronaries.
Study NCT03848650 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FFR
Description: A guide wire-based procedure that can accurately measure blood pressure and flow through a specific part of the coronary artery. FFR is done through a standard diagnostic catheter at the time of a coronary angiogram (a.k.a. cardiac catheterization).
Study NCT05951062 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: behavior management for anti-hypertensive medication
Description: five sessions of educational interview and home visiting to improve medication-related self-management skills
Study NCT05951062 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: placebo group
Description: treatment as usual
Study NCT04142853 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Training intervention + Dance intervention
Description: Training intervention + Dance intervention
Study NCT04142853 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training intervention + Dance intervention
Description: Training intervention + Dance intervention
Study NCT02029625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVP-1205
Description: rosuvastatin/ezetimibe fixed dose combination orally, once daily on Period 1 or Period 2
Study NCT02029625 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rosuvastatin and ezetimibe
Description: coadministration of rosuvastatin and ezetimibe orally, once daily on Period 1 or Period 2
Study NCT02450383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acellular Dermal Matrix
Description: Placement of acellular dermal matrix (Alloderm®) on the buccal/coronal aspect of the alveolar ridge at the time of implant placement, following a two-stage approach
Study NCT02450383 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autologous subepithelial connective tissue graft
Description: Placement of autologous subepithelial connective tissue graft on the buccal/coronal aspect of the alveolar ridge at the time of implant placement, following a two-stage approach
Study NCT03895086 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Specific Physical Activity
Description: An individual one hour face-to-face session conducted by adaptated physical activities teachers followed by eight telephone sessions by physical therapists and adaptated physical activities teachers (4 sessions each)
Study NCT03895086 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Classic Physical Activity
Description: One session per week in groups conducted by adaptated physical activities teachers of Siel Bleu association
Study NCT00952445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T0903131 Besylate
Description: Once daily, oral
Study NCT02801292 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ketamine
Description: Single bolus of Ketamine .25 milligrams per kilogram of weight.
Study NCT02329704 — intervention group
Intervention type: PROCEDURE
Intervention: HBA Testing
Description: The Hyaluronic Binding Assay (HBA®) is an important diagnostic tool for suspected male infertility in the analysis of semen. In a matter of minutes the HBA® slide provides an answer to the proportion of mature binding spermatozoa in the sample (The HBA® score %).~By using HBA slide we can count the physiologically active sperms at each sample and calculate percentage of active sperms with reference to post processing count from 3rd investigating arm.
Study NCT02329704 — intervention group
Intervention type: BIOLOGICAL
Intervention: Bacterial contamination
Description: Routine bacterial culture using Blood Agar culture plates for 10 micron finally washed samples, to confirm presence of any bacteria contamination caused by carry over during processing.
Study NCT04668729 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chiropractic Manipulation
Description: Lumbar vertebrae and sacroiliac joints of the participants that have lost their normal joint motion will be detected by static and dynamic palpation techniques.~Lumbal Chiropractic HVLA Spinal Manipulation: HVLA manipulation will be applied in the left transverse process of the lumbar vertebra (mammillary process) of the participants whose problem is to the left of the lumbar vertebra.~Sacroiliac Chiropractic HVLA Manipulation: Participants who lost normal joint motion in the anterior and superior directions in the left sacroiliac joint will be treated with HVLA manipulation in the left PSIS (Posterior Superior Iliac Spine: PSIS). Participants who have lost normal joint motion in the left sacroiliac joint in the posterior and inferior directions will be applied HVLA manipulation in the left ischial tuberosity.~For both applications, it will be positioned in the opposite position for the problems on the right and the application will be made in the opposite position.
Study NCT01961466 — intervention group
Intervention type: OTHER
Intervention: psychological and social self-administered questionnaires
Study NCT01214031 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Confocal laser endomicroscopy (CLE)
Description: Confocal laser endomicroscopy (CLE) is another novel imaging tool for enabling histopathologic diagnosis in vivo during endoscopy. Specially designed confocal endoscopes have the confocal laser microscope integrated to the distal tip of the conventional endoscope. This provide images at a cellular level that have been shown to have a high sensitivity, specificity and accuracy
Study NCT04300244 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UV1 vaccine + leukine
Description: The mode of action of UV1 is to activate the immune system to induce T cells directed against telomerase (hTERT). UV1 vaccination amplifies the pool of hTERT specific tumor-reactive T cells from the naive repertoire and has the potential to increase the breadth and diversity of the tumor-reactive T cell response (epitope spreading). Vaccination with UV1 can thus provide the basis for increased efficacy of checkpoint inhibition therapy, by augmenting the pool of tumor specific T cells in patients with limited or insufficient numbers of T cell clones spontaneously primed by tumor antigens. Reciprocally, the efficacy of UV1 vaccination may be enhanced in combination with checkpoint inhibitors, since the clonal expansion and effector activity of UV1 induced T cells will otherwise be restricted by intrinsic immune regulatory and tumor induced suppressor mechanisms.
Study NCT04300244 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ipilimumab
Description: The responses to ipilimumab and nivolumab combination therapy seen in MPM is encouraging.
Study NCT04300244 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ipilimumab
Description: The responses to ipilimumab and nivolumab combination therapy seen in MPM is encouraging.
Study NCT04300244 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: The responses to ipilimumab and nivolumab combination therapy seen in MPM is encouraging.
Study NCT02733328 — intervention group
Intervention type: PROCEDURE
Intervention: CPB Surgery
Study NCT00952445 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily, oral
Study NCT00938821 — intervention group
Intervention type: PROCEDURE
Intervention: Caudal block
Description: Chart review of patients that received very low dose morphine administered caudally (M) and plain caudal block with Ropivacaine or Marcaine (B)from October 2008 to October 2009.
Study NCT03038607 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: This group were subjected to aspirin 75 mg once daily for 6 weeks.
Study NCT04271371 — intervention group
Intervention type: OTHER
Intervention: Not yet developed
Description: A prototype intervention will be developed over Phase 1 \& 2 and piloted in Phase 3 of this study.
Study NCT01460875 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant interferon alfa-2b
Description: Given SC
Study NCT01460875 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Blood for use in correlative studies approximately 30 ml 30 x 106 peripheral blood mononuclear cell (PBMCs) will be drawn on day 1 every other week during the first 12 weeks just prior to treatment and at 1 and 4 hours post therapy.
Study NCT04323137 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Risk reduction
Description: Mailed letter, SMS, and/or patient portal message
Study NCT04323137 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medical records-based recommendation
Description: Mailed letter, SMS, and/or patient portal message
Study NCT04323137 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Algorithm-based recommendation
Description: Mailed letter, SMS, and/or patient portal message
Study NCT01587261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: Treatment Group will receive a dose of 66 mg/kg/hr of ascorbic acid injection for 24 hours after injury
Study NCT01587261 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lactated Ringers solution will be given at a similar volume to what the treatment group will receive
Study NCT02180256 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endometrial Scratching
Description: The intentional damage to the endometrium performed with the objective of improving the reproductive outcomes of women desiring pregnancy.
Study NCT02150057 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Breg Fusion Unloading Brace
Description: This group is assigned to wear an unloading brace and report pain and quality of life by completion of a pain diary and related questionnaires.
Study NCT02090049 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Puravita Breakfast
Description: The study was done in duplicate i.e two different days each meal (control and experimental) separated at least one week in time. Subjects were instructed to consume the test meal within 10 min from commencement. They subsequently completed VAS on appetite sensation every 30 min until a total of 4 hours. At the end of the test day, an ad libitum lunch consisting of a standardized pizza (17E% protein, 34E% fat and 49E% carbohydrate) and water (300 ml) was served. The subjects were instructed to eat until comfortably satisfied. Food intake was registered and energy intake (EI) calculated afterwards.
Study NCT02090049 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: The control breakfast consisted of white bread (85 g), jam (10 g) and margarine (2 g) to adjust for energy density, fat and sugar levels.
Study NCT00470093 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant interferon-α
Study NCT00470093 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant interleukin-6
Study NCT00664560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PN 400 (VIMOVO)
Description: 500 mg naproxen/20 mg esomeprazole bid
Study NCT00664560 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: celebrex
Description: 200 mg celecoxib qd
Study NCT00664560 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: sugar pill bid
Study NCT04300244 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: nivolumab
Description: The responses to ipilimumab and nivolumab combination therapy seen in MPM is encouraging.
Study NCT01812759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl Nasal Spray
Description: 100 mcg nasal spray administered in each nostril.
Study NCT02759679 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Human breath samples
Study NCT01934660 — intervention group
Intervention type: DRUG
Intervention: Fludeoxyglucose F18
Study NCT00664560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rescue Antacid
Description: Antacid Tablets
Study NCT00664560 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rescue Antacid
Description: Antacid Tablets
Study NCT00664560 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rescue Antacid
Description: Antacid Tablets
Study NCT03454399 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Suction orogastric tube which is attached to TEE probe
Description: Suction orogastric tube which is attached to TEE probe
Study NCT01344681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Micafungin sodium
Description: 1. Treatment period (active treatment): an average 14 days~2. Dosage:~   - Study Drug: Micafungin sodium (mycamine ® injections 50mg/vial) 2 vials (100mg / day)~3. Administration Method:~   * Study Drug: 3-5 days after fever begins. Infusion one time a day (one hour). Termination of treatment after maintaining fever for three days or the recovery of neutrophils with no fever.